{"nctId":"NCT03830866","briefTitle":"Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)","startDateStruct":{"date":"2019-02-15","type":"ACTUAL"},"conditions":["Locally Advanced Cervical Cancer"],"count":770,"armGroups":[{"label":"Durvalumab (intravenous infusion)","type":"EXPERIMENTAL","interventionNames":["Biological: Durvalumab","Drug: Cisplatin","Drug: Carboplatin","Radiation: external beam radiation therapy (EBRT) + brachytherapy"]},{"label":"Placebo (matching placebo for intravenous infusion)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Cisplatin","Drug: Carboplatin","Radiation: external beam radiation therapy (EBRT) + brachytherapy"]}],"interventions":[{"name":"Durvalumab","otherNames":[]},{"name":"Cisplatin","otherNames":[]},{"name":"Carboplatin","otherNames":[]},{"name":"external beam radiation therapy (EBRT) + brachytherapy","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nFor inclusion in the study, patients should fulfill the following criteria:\n\n1. Female\n2. Aged at least 18 years\n3. Documented evidence of cervical adenocarcinoma or squamous carcinoma FIGO (2009) Stages IB2 to IIB node positive or FIGO (2009) IIIA-IVA any node\n4. No prior chemotherapy or radiotherapy for cervical cancer\n5. WHO/ECOG performance status of 0-1\n6. At least 1 lesion, not previously irradiated, that qualifies as a RECIST 1.1 Target Lesion at baseline.\n\nExclusion Criteria:\n\nPatients should not enter the study if any of the following exclusion criteria are fulfilled:\n\n1. Diagnosis of small cell (neuroendocrine) histology or mucinous adenocarcinoma cervical cancer\n2. Intent to administer a fertility-sparing treatment regimen\n3. Undergone a previous hysterectomy\n4. Evidence of metastatic disease per RECIST 1.1 including lymph nodes â‰¥15 mm (short axis) above the L1 cephalad body, in the inguinal region or outside the planned radiation field.\n5. History of allogeneic organ transplantation\n6. Active or prior documented autoimmune or inflammatory disorders\n7. Uncontrolled intercurrent illness\n8. History of another primary malignancy and active primary immunodeficiency","healthyVolunteers":false,"sex":"FEMALE","genderBased":true,"genderDescription":"Female: only female participants are being studied","minimumAge":"18 Years","maximumAge":"130 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-free Survival (PFS) Based on the Investigator Assessment According to RECIST 1.1 or Histopathologic Confirmation of Local Tumour Progression","description":"PFS defined as time from date of randomisation until date of tumour progression or death by any cause, regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to progression","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival (PFS) Based on the Investigator Assessment According to RECIST 1.1 or Histopathologic Confirmation of Local Tumour Progression, PD-L1 Expression >= 1%","description":"PFS defined as time from date of randomisation until date of tumour progression or death by any cause, regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to progression","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (Count)","description":"Number of Participants with Overall Survival (OS) where OS was defined as the time from the date of randomisation until death by any cause","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"112","spread":null}]},{"measurements":[{"groupId":"OG000","value":"294","spread":null},{"groupId":"OG001","value":"273","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (Duration)","description":"Time from the date of randomisation until death by any cause","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR)","description":"Percentage of evaluable patients with an Investigator-assessed visit response of complete response (CR) or partial response (PR). CR defined as disappearance of all target and non-target lesions and no new lesions. PR defined as \\>= 30% decrease in the sum of diameters of target lesions (compared to baseline) and no new non-target lesion","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.6","spread":null},{"groupId":"OG001","value":"80.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Complete Response Rate","description":"Percentage of evaluable patients with an overall visit response of Complete Response (disappearance of all target and non-target lesions)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.9","spread":null},{"groupId":"OG001","value":"40.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DoR) in Patients With Complete Response (CR)","description":"Time from date of first documented CR until date of documented progression or death in the absence of progression. For patients who did not progress their DoR was their Progression-free survival censoring time","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":113,"n":385},"commonTop":["Nausea","Anaemia","Diarrhoea","Vomiting","Constipation"]}}}